Stock price when the opinion was issued
NA's leading death-care company. Consolidator in a fragmented industry. 15-16% market share. Size and scale are a meaningful advantage, as is financial strength. Two closest rivals are encountering financial difficulties. 30% ROE and rising.
After a couple of tough Covid years, should return to historic 14% earnings as well as dividend growth. Good combination of value and high-visibility, non-cyclical, non-discretionary growth. Testing all-time highs. Yield is 1.7%.
May be able to ramp up M&A a bit. Many died before their time during Covid, then there was a lull, and now getting back to normal averages. Benefits from scale and operating efficiencies as it makes acquisitions. Dominant position.